



**Advancing Cancer Treatment *Through Safer Drug Delivery***

**FOR IMMEDIATE RELEASE**

**SciTech Announces Launch of Equity Crowdfunding Campaign on StartEngine**

(GROSSE POINTE FARMS, MI) March 15, 2022 – SciTech Development LLC, a specialty pharmaceutical company, is pleased to announce the launch of its crowdfunding campaign on StartEngine. SciTech plans to grow the company, scale-up clinical drug manufacturing, and to commence the company's first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin's lymphoma. Non-Hodgkin's lymphomas are cancers that begin in the lymphatic system, which is part of the body's germ-fighting immune system.

SciTech's patented lead drug candidate ST-001 nanoFenretinide is a combination of the company's proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. We are also pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).

Earle Holsapple, President of SciTech Development relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech's scientific breakthroughs will have a profound impact on patients who are battling cancer.

Visit <https://www.startengine.com/scitechdevelopment> to invest in SciTech's crowdfunding campaign, early investors qualify for time-based bonuses. For company, product,

and investor information visit [www.SciTechSDP.com](http://www.SciTechSDP.com). Detailed information regarding SciTech's science and the company can be found at [www.SciTechDevelopment.com](http://www.SciTechDevelopment.com).

### **About SciTech Development**

SciTech Development LLC is a specialty pharmaceutical company dedicated to advancing breakthrough cancer treatments. SciTech has developed a powerful, new Drug Delivery Platform (SDP) that will revolutionize how safe and promising, yet challenged drugs, can be delivered to kill cancer. SciTech has developed its first, patented drug candidate ST-001-nanoFenretinide that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. SciTech's innovations will impact its mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SciTech Development is in the pre-revenue clinical stage of development.

### **About StartEngine**

Founded in 2014, StartEngine is an equity crowdfunding platform that gives all types of investors access to startup investing opportunities. The crowdfunding platform is useful to both founders and startups in search of funding for operational expenses and business expansion. More information regarding StartEngine can be found online at <https://www.startengine.com/>

### **Investment Inquiries**

For terms of the offering and investment inquiries, visit: <https://www.startengine.com/scitechdevelopment>

### **Forward-Looking Information**

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also

takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



#####